Model NO.: 57-83-0
CAS: 763113-22-0
M. F.: C24h23fn4o3
M. W: 434.46
Trademark: SL
Transport Package: Discreet Package
Specification: Raw Powder
Origin: China
Model NO.: 57-83-0
CAS: 763113-22-0
M. F.: C24h23fn4o3
M. W: 434.46
Trademark: SL
Transport Package: Discreet Package
Specification: Raw Powder
Origin: China
Basic Information:Product name: olapani
CAS: 763113-22-0
Standard: enterprise standard
Natural/synthetic: synthetic
Level: medical level
Content: 99%
Appearance: white powder
Packaging: 1KG/ aluminum foil bag detachable
Category: medical materials
Industry: medicine
Field: inhibitors
Extended product: olapani capsule
Application: maintenance therapy for patients with severe recurrent ovarian cancer with breast cancer susceptibility gene (BRCA) mutation and sensitivity to platinum-based drugs
Description:
Olaparib ACTS effectively on Brca1. P53 breast tumors (intraperitoneal injection at 50mg /kg per day), but for hr-deficient Ecad; P53 breast tumors have no effect. Olaparib has no dose - limiting toxicity in tumor-carrying mice. Olaparib has been used to treat tumors with BRCA mutations, such as ovarian cancer, breast cancer and prostate cancer. In addition, Olaparib is selective in inhibiting tumor cells with ATM defects, indicating that Olaparib can be used as a potential reagent for the treatment of lymphatic tumors with ATM mutations.
If you want to know more about our products,please search
http://www.slsteroid.com/. Basic Information:
Product name: olapani
CAS: 763113-22-0
Standard: enterprise standard
Natural/synthetic: synthetic
Level: medical level
Content: 99%
Appearance: white powder
Packaging: 1KG/ aluminum foil bag detachable
Category: medical materials
Industry: medicine
Field: inhibitors
Extended product: olapani capsule
Application: maintenance therapy for patients with severe recurrent ovarian cancer with breast cancer susceptibility gene (BRCA) mutation and sensitivity to platinum-based drugs
Description:
Olaparib ACTS effectively on Brca1. P53 breast tumors (intraperitoneal injection at 50mg /kg per day), but for hr-deficient Ecad; P53 breast tumors have no effect. Olaparib has no dose - limiting toxicity in tumor-carrying mice. Olaparib has been used to treat tumors with BRCA mutations, such as ovarian cancer, breast cancer and prostate cancer. In addition, Olaparib is selective in inhibiting tumor cells with ATM defects, indicating that Olaparib can be used as a potential reagent for the treatment of lymphatic tumors with ATM mutations.
If you want to know more about our products,please search
http://www.slsteroid.com/.